EMulate Therapeutics, Inc. (EMTx) announces the acceptance of a publication of its pre-clinical animal model, testing the effect of its ulRFE® paclitaxel (A1A) signal against a DIPG tumor cell line.

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

Please provide your email address to receive an email when new articles are posted on . Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Please provide your email address to receive an email when new articles are posted on . Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for ...

Diffuse intrinsic pontine glioma (DIPG) is an almost universally fatal brain pediatric tumor and the only tumor indication where palliative radiotherapy is the current standard of care. Although ...